

Amendments to the Claims:

✓
This listing of claims will replace all prior versions and listings of claims in the application:

DX
Sub
El
Claim 1. (currently amended): A method for preventing constrictive vascular remodeling comprising a controlled delivery, by release from ~~an intraluminal medical device~~ a stent, of a compound having anti-proliferative and anti-inflammatory properties in therapeutic dosage amounts in the range from about thirty-five micrograms per fifteen to eighteen millimeters of stent to about four hundred thirty micrograms per fifteen to eighteen millimeters of stent, the compound substantially reducing in-lesion lumen loss both proximate and distal to the ~~intraluminal medical device~~ stent, the compound being incorporated in a polymeric matrix.

Claim 2. (previously presented): The method for preventing constrictive remodeling according to Claim 1, further includes utilizing the compound to block a proliferation of fibroblasts in a vascular wall in response to injury, thereby reducing a formation of vascular scar tissue.

Claim 3. (previously presented): The method for preventing constrictive remodeling according to Claim 2, wherein the compound comprises rapamycin.

Claim 4. (previously presented): The method for preventing constrictive remodeling according to Claim 2, wherein the compound comprises analogs and congeners that bind a high-

Serial No. 09/850,293

affinity cytosolic protein, FKBP12, and possesses pharmacologic properties equivalent to rapamycin.

Claim 5. (previously presented): The method for preventing constrictive remodeling according to Claim 1, further includes utilizing the compound to affect a translation of certain proteins involved in a collagen formation or metabolism.

Claim 6. (previously presented): The method for preventing constrictive remodeling according to Claim 5, wherein the compound comprises rapamycin.

*DX
Sub
EI*
Claim 7. (previously presented): The method for preventing constrictive remodeling according to Claim 5, wherein the compound comprises analogs and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses pharmacologic properties equivalent to rapamycin.

Claim 8. (currently amended): A drug delivery device for treating constrictive vascular remodeling comprising:

~~an intraluminal medical device~~ a stent; and

a therapeutic dosage, in the range from about thirty-five micrograms per fifteen to eighteen millimeters of stent to about four hundred thirty micrograms per fifteen to eighteen millimeters of stent, of an agent having anti-proliferative and anti-inflammatory properties releasably affixed to the ~~intraluminal medical device~~ stent for treatment of constrictive vascular remodeling, the agent substantially reducing in-lesion

Serial No. 09/850,293

lumen loss both proximal and distal to the intraluminal medical device, the agent being incorporated in a polymeric matrix.

Claim 9. (previously presented): The drug delivery device according to Claim 8, wherein the agent blocks a proliferation of fibroblasts in a vascular wall in response to injury, thereby reducing a formation of vascular scar tissue.

Claim 10. (original): The drug delivery device according to Claim 9, wherein the agent comprises rapamycin.

34b
E1
Dx
Claim 11. (previously presented): The drug delivery device according to Claim 9, wherein the agent comprises analogs and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses pharmacologic properties equivalent to rapamycin.

Claim 12. (previously presented): The drug delivery device according to Claim 8, wherein the agent affects the translation of certain proteins involved in collagen formation or metabolism.

Claim 13. (original): The drug delivery device according to Claim 12, wherein the agent comprises rapamycin.

Claim 14. (previously presented): The drug delivery device according to Claim 12, wherein the agent comprises analogs and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses pharmacologic properties equivalent to rapamycin.

Claim 15. (cancelled)

Serial No. 09/850,293